About the journal
Blood Neoplasia is an open-access journal published by Elsevier in United States, publishing in english. It is listed in DOAJ according to the sources read. Declared publication charge: 3,000 USD. Declared review time at DOAJ: 14 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Elsevier
- ISSN
- 2950-3280
- Country
- United States
- Languages
- english
- Access
- Open access
- Declared publication charge
- 3,000 USD
- Articles in DOAJ
- 108
- Declared review time
- 14 weeks
- Declared peer-review model
- peer_review
- Official website
- https://www.sciencedirect.com/journal/blood-neoplasia
Index listings
- DOAJ · 2024-11-18
- Indexing
- DOAJ
- APC
- 3,000 USD
- Declared review time (DOAJ)
- 14 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
108
Most recent article
last month
Average review time (journal-declared via DOAJ)
14weeks
Works in OpenAlex
260
Last recorded publication year
2026
h-index
9
i10-index
9
From OpenAlex open data (CC0).
Editorial & policy11
- Last DOAJ review date
- 2026-04-27
- Added to DOAJ
- 2024-11-18
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Declared digital preservation
- CLOCKSSPortico
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Editorial board
- Official page ↗
- Open references deposited at Crossref
- 90%
- ORCID iDs in current deposits
- 98%
- Deposits licence metadata at Crossref
- ✓
- APC waiver policy
- View policy
- Peer-review policy
- View policy
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 9918841988906676
Classification2
Subjects (DOAJ)
LCC codes
Subject areas
- Acute Myeloid Leukemia Research
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
Show all subjects (50)
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- CAR-T cell therapy research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Protein Degradation and Inhibitors
- Retinoids in leukemia and cellular processes
- Retinoids in leukemia and cellular processes
- Cutaneous lymphoproliferative disorders research
- Cutaneous lymphoproliferative disorders research
- Immune Cell Function and Interaction
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- Viral-associated cancers and disorders
- Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cell Transplantation
- CNS Lymphoma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Histone Deacetylase Inhibitors Research
- Eosinophilic Disorders and Syndromes
- Immunodeficiency and Autoimmune Disorders
- Eosinophilic Disorders and Syndromes
- Immunodeficiency and Autoimmune Disorders
- CNS Lymphoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Immunotherapy and Biomarkers
- T-cell and Retrovirus Studies
- T-cell and Retrovirus Studies
- Cytokine Signaling Pathways and Interactions
- Cancer Genomics and Diagnostics
- Cell death mechanisms and regulation
- Cytokine Signaling Pathways and Interactions
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Cell death mechanisms and regulation
- Cancer Treatment and Pharmacology
- Childhood Cancer Survivors' Quality of Life
- Cancer Treatment and Pharmacology
Keywords (DOAJ)
- hematology
- hematologic malignancy
- leukemia
- lymphoma
- multiple myeloma
- myeloproliferative neoplasms
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ